MKP11093 has shown strong results in preclinical studies with a promising safety and selectivity profile
The Ma’anshan site approval covers pastilles, oral liquids, and powders
Targeting a 10% reduction in energy and water consumption, and a 30% cut in carbon emissions across facilities by 2025
The cGMP-4 facility will further strengthen the company's ability to serve global partners
Tourmaline Bio is a clinical-stage biopharmaceutical company developing pacibekitug, an anti-IL-6 mAb, as a treatment option for atherosclerotic cardiovascular disease
Breakthrough UNITY 4D Phaco delivers up to 2X faster nucleus removal and 41% less energy into the eye
New Bay Area building marks significant progress as part of $32 billion US investment projected to create $43 billion in economic value
Agreement further expands Aptar Pharma’s leading position in nasal delivery solutions and addresses significant unmet needs of delivering drugs locally over extended periods
Argo will receive an upfront payment of $160 million, an option for Profit & Loss split across multiple geographies and potential near-term equity
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
